NCT06885931招募中不适用
Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System
Amber Therapeutics Ltd8 个研究点 分布在 3 个国家目标入组 86 人开始时间: 2025年6月24日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 86
- 试验地点
- 8
- 主要终点
- Summative rates of procedural and device related adverse events and device deficiencies.
研究概览
简要总结
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female. NB: the definition of female refers to sex at birth.
- •Adult: aged ≥ 22 years (at the time of informed consent signature).
- •Patient self-reports both stress and urge episodes (clinician-opinion on history taking).
- •Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.
- •Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.
- •Able and willing to voluntarily sign informed consent form.
- •Able to participate in all testing and follow-up clinic visits associated with study protocol.
- •Patient is mobile and able to use a toilet.
- •In the opinion of the Investigator, the patient is capable of independently using the system components (after training).
排除标准
- •Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.
- •Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.
- •In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.
- •Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.
- •History of major psychiatric or personality disorder.
- •Any neurological condition that in the opinion of the investigator may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or complete spinal cord injury).
- •Uncontrolled type I or type II diabetes (as defined by their routine care clinician or HBA1C ≥ 7.0).
- •History of cancer within 5 years prior to enrolment, except for a cancer that was determined to be free of systemic cancer risk, such as basal cell carcinoma.
- •Patient is taking antiplatelet and/or anticoagulant drugs including warfarin or newer alternatives (e.g., rivaroxaban, apixaban, dabigatran, edoxaban) which cannot be paused prior to surgery, or has a bleeding disorder that cannot be corrected prior to surgery.
- •Any clinical reason that, in the opinion of the Investigator, may compromise patient's safety during the study.
- •Currently participating in another interventional study. This excepts purely observational studies, e.g., registries.
- •Patient participation in vigorous physical activities where these cannot be restricted for a period of 6 weeks post-implantation.
- •Patient unwilling to stop any future participation in scuba diving below 10m. BMI ≥ 40kg/m2 or waist circumference > 127cm
- •Documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone.
- •Skin, orthopedic or neurological anatomical limitations at the site of implant that could prevent successful placement of an electrode or IPG. This includes active perineal sepsis or perianal sepsis (e.g., anal fistula and pilonidal sinus).
- •Knowledge of planned MRIs, diathermy, medical microwave exposure, high output ultrasonic exposure, or medical RF energy exposure.
- •Implantable neurostimulator or antennae, pacemaker or defibrillator in-situ (anywhere in body).
- •Exclusion Criteria (Urological):
- •Known diagnosis of interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines. Diagnosis of any other chronic pelvic or regional pain syndrome
- •Documented bladder emptying syndrome including neurogenic bladder.
- •Known abnormal post void residual (> 100 ml).
- •Any prolapse (symptomatic or asymptomatic) currently at or below the hymenal level Known urinary tract mechanical obstruction such as urethral stricture and/or bladder neck contracture.
- •Current symptomatic urinary tract infection (UTI) or more than 3 culture-proven UTIs in past year.
- •Current diagnosis of vesicoureteral reflux
- •Current diagnosis of bladder stones
- •History of bladder tumour (benign or malignant) -Suspected or proven pudendal nerve entrapment syndrome. In patients with co- existent chronic pelvic pain and urinary incontinence symptoms, Nantes criteria will be used for screening. Patients meeting essential criteria will be excluded from the study.
- •Suspected or proven severe pudendal nerve damage at discretion of clinician with or without specialist investigations
- •Any previous experience of pudendal nerve stimulation using an implanted lead.
- •Previous failure of SNM therapy (based on implantation; failed test phase is not an exclusion)
- •Major previous urethral or bladder surgery (excisional or reconstructive) at discretion of investigator
- •SUI surgery e.g. urethral slings, tapes, and bulking agents colposuspension within last 2 years; > 2 years at discretion of investigator
- •Prolapse surgery e.g. colposuspension / colporrhaphy within last 12 months with current confirmation via pelvic exam of no recurrence > or = to Stage 2 pelvic organ prolapse
- •Previous use of bladder botox injections within last 6 months
研究组 & 干预措施
Cohort A
Experimental
Mixed Urinary Incontinence cohort
干预措施: Pudendal neuromodulation (Device)
Cohort B
Experimental
Extended indications cohort (Stress Urinary Incontinence, Urge Urinary Incontinence, Chronic Pelvic Pain, AURA-2)
干预措施: Pudendal neuromodulation (Device)
结局指标
主要结局
Summative rates of procedural and device related adverse events and device deficiencies.
时间窗: 12 months
Urinary Distress Inventory score change
时间窗: 6 months
Score minimum 0 to maximum 100. Lower score is better outcome.
Proportion of participants requiring surgical reintervention.
时间窗: 12 months
次要结局
- Urinary Distress Inventory (total, total Mixed Urinary Incontinence) score change(12 months)
- Patient Global Impression of Improvement score change(12 months)
- 3-day voiding diary number of events(12 months)
- 24-hour pad test weight change(12 months)
- The International Consultation on Incontinence Questionnaire score change(12 months)
- General Anxiety Disorder score change(12 months)
- Patient Health Questionnaire 9 score change(12 months)
- World Health Organization Disability Assessment Schedule score change(12 months)
- European Quality of Life 5 Dimension Questionnaire score change.(12 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
PRISM Neurofeedback Training for MDD Anhedonic PatientsAnhedoniaDepressionNCT05869708GrayMatters Health Ltd.19
已完成
不适用
Effectiveness of Percutaneous Neuromodulation in the Treatment of Cervical Pain in University Students.Neck PainNCT06480851CEU San Pablo University52
招募中
不适用
pBFS-guided Dual-target cTBS for Aphasia After StrokeAphasiaStrokeNCT05957354Changping Laboratory60
已完成
不适用
Multimodal Neuromodulation in Individuals With Parkinson's DiseaseParkinson DiseaseNCT05105776Ryan D'Arcy32
Enrolling By Invitation
不适用
Sacral Neuromodulation in Neurogenic PatientsNeurogenic BowelUrge IncontinenceFecal IncontinenceNeurogenic BladderRetention, UrinaryOveractive BladderNCT05688644Omri Schwarztuch Gildor100